Kura Oncology, Inc., a clinical-stage biopharmaceutical innovator, and Japan-based pharmaceutical leader Kyowa Kirin Co., Ltd., have entered into a strategic partnership that could redefine treatment for acute myeloid leukemia (AML). The collaboration focuses on ziftomenib, an investigational oral menin inhibitor that has garnered attention as a potential breakthrough therapy for genetically defined AML patients. This […]
In a significant advancement in cancer treatment, Thermo Fisher Scientific Inc. (NYSE: TMO) has partnered with the National Cancer Institute (NCI), a component of the National Institutes of Health, to launch the myeloMATCH precision medicine umbrella trial. This initiative aims to revolutionize the treatment landscape for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) through […]
Immune-Onc Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of innovative therapies in immunology and oncology, has achieved a significant milestone with the U.S. Food and Drug Administration’s (FDA) recent Orphan Drug Designation for IO-202. This designation is a crucial step forward in the treatment of chronic myelomonocytic leukemia (CMML), a rare form […]
In a significant development for cancer research, Kurome Therapeutics Inc. has announced the U.S. Food and Drug Administration (FDA) clearance of the Investigational New Drug (IND) application for KME-0584, propelling the biotech firm into a Phase 1 clinical trial for patients with relapsed/refractory (R/R) Acute Myeloid Leukemia (AML) and high-risk (HR) Myelodysplastic Syndromes (MDS). Slated […]
Hemogenyx Pharmaceuticals plc, a London-based biopharmaceutical company, has received approval from the U.S. Food and Drug Administration (FDA) to proceed with its Phase I clinical study of HEMO-CAR-T, marking a significant milestone in the treatment of acute myeloid leukemia (AML). This development follows the FDA’s decision to lift the clinical hold on the Investigational New […]
Invivoscribe and Complete Genomics have announced a partnership aimed at developing and commercializing biomarker tests on the latter’s next-generation sequencing (NGS) platforms. The collaboration, covering worldwide territories, focuses on oncology and cancer research. Based in California, Invivoscribe is specialized in precision diagnostics and reagents for hematologic malignancies and molecular diagnostics. Also based in California, Complete […]
Rigel Pharmaceuticals has received approval from the US Food and Drug Administration (FDA) for its Rezlidhia (olutasidenib) capsules for relapsed or refractory (R/R) acute myeloid leukemia (AML) in adult patients. Rezlidhia is indicated for patients with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as identified by an FDA-approved test. The oral, small molecule and mutant isocitrate […]
Medexus Pharmaceuticals said that its strategic partner medac has resubmitted the new drug application (NDA) for treosulfan with the US Food and Drug Administration (FDA). Treosulfan is part of a preparative regimen for allogeneic hematopoietic stem cell transplantation (allo-HSCT). It is intended to be used in combination with fludarabine for the treatment of eligible patients […]
CA-4948 phase 1 clinical trial : US biotech company Curis said that it has dosed the first patient with CA-4948 in a phase 1 clinical trial that is evaluating the small molecule IRAK4 kinase inhibitor for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). The phase 1 clinical trial for CA-4948 will […]
Gilead Sciences has completed its previously announced $4.9 billion acquisition of Forty Seven, a clinical-stage immuno-oncology company based in California. The immuno-oncology company has been acquired by the US biotech company for $95.50 per share in cash to become the latter’s fully-owned subsidiary. Forty Seven will be delisted from the Nasdaq Global Select Market. The […]
